The Cell Analysis Market Seeks Prosperous Horizon: Anticipating 10-11% Growth Rate by 2028
The increasing need for cell-based assays in drug
discovery, increased funding for cell-based research, a spike in drug
development activities, the increasing frequency of chronic illnesses, and
technical improvements in cell analysis are the primary drivers driving the
market. Fill out a simple inquiry for a sample report to discover more about
the research.
Cell analysis include
analyzing and quantifying characteristics such as cell count, cellular state,
viability, proliferation, and toxicity caused by chemicals and cells.
Cell-based assays yield detailed results for fundamental research, drug
discovery & development, and clinical applications.
To learn more
about the research, fill out a quick inquiry for a sample report: https://meditechinsights.com/cell-analysis-market/request-sample/
Technological
advancements drive growth in the Cell Analysis Market
The incorporation
of modern technologies is considerably driving the growth of the cell analysis
market. This entails combining new and current technology to provide more
robust and precise tools for researchers and healthcare practitioners. As a
result, there is a distinct growing trend in technological integration in cell
analysis.
- In May 2023, Deepcell, a pioneer in AI-powered
single-cell analysis, has introduced the REM-1 platform. Benchtop
instruments, the Axon data suite, and the Human Foundation Model are all
part of this complete platform. The REM-1 platform integrates single-cell
sorting, imaging, and analysis to provide high-dimensional cell morphology
analysis and sorting, opening up new paths for research in domains such as
developmental biology, stem cell biology, cancer biology, gene therapy,
and functional screening. Deepcell expects its AI-powered method to
cellular analysis to greatly boost biological research, ushering in a new
era of discovery.
- In a parallel development
in January 2023, Axion BioSystems expanded its Omni
live-cell imaging product family by introducing the Omni Pro 12 platform.
Equipped with integrated robotics and a multi-plate design compatible with
standard incubators, this platform enhances flexibility and efficiency for
live-cell imaging experiments for scientists and drug developers. The Omni
Pro 12 is a valuable tool for advancing research in critical areas such as
oncology, immunology, and stem cell biology, with the potential to
facilitate the development of innovative drugs and therapeutics
The Growing
Importance of Cell-Based Screening in Modern Drug Discovery is fueling the Cell Analysis Market
The use of
cell-based screening assays has increased in drug development efforts to better
understand the complexities involved. Cell biology, bioinformatics, molecular
biology, genomics, and proteomics advances have resulted in massive data
gathering. As a result, the importance of using cell-based assays in the drug
development pipeline has expanded. Similarly, the Human Genome Project has
yielded a plethora of drug-screening targets. The current rapid expansion of
therapeutic targets and leads has accelerated the use of cell-based assays for primary
and secondary screening in the drug development process.
Cell Analysis
Market: Competitive Landscape
Some of the key players operating
in the market include Danaher, Thermo Fisher Scientific, Becton Dickinson and
Company, Merck KGaA, General Electric, Agilent Technologies, Bio-Rad
Laboratories, Olympus Corporation, Fluidigm Corporation, Miltenyi Biotec, Cell
Biolabs, Creative Bioarray, BioStatus Limited, NanoCellect Biomedical, Promega
Corporation, CELLINK, among others.
Organic and
Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in
the Cell Analysis Market
Players operating in this market are adopting organic and inorganic growth strategies such as launching new products, acquiring related firms, and entering into mergers & collaborations to garner higher market share. For instance,
- In the year 2023, the United States-based company Becton, Dickinson and Company introduced a Spectral Cell Sorter, integrating high-speed cell imaging. This product seamlessly merges real-time imaging technology with spectral flow cytometry
- In Dec 2023, CS Genetics announced that they are working on commercializing a simple, flexible, and easily scalable instrument-free, single-cell analysis technology
The
application of novel cell-based assays in cancer research, promising prospects
of single-cell sequencing, growing prospects in emerging economies, thriving
biopharma industry, and aggressive organic and inorganic growth strategies
adopted by players are expected to drive the Cell Analysis Market in the coming
years.
Get Detailed Insights on the Cell Analysis
Market @ https://meditechinsights.com/cell-analysis-market/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused
business research & insights firm. Our clients include Fortune 500
companies, blue-chip investors & hyper-growth start-ups. We have successfully
completed 100+ projects in Digital Health, Healthcare IT, Medical Technology,
Medical Devices & Pharma Services.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment